From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

e-Therapeutics - more on that transaction to re-buy Searchbolt: were the rotting kippers stuffed with rotting pickled anchovies?

By Nigel Somerville, the Deputy Sheriff of AIM | Sunday 15 May 2016


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Tom Winnifrith has already stuck the knife into e-Therapeutics (ETX) over its related party deal to re-buy Searchbolt – a company it had previously spun off as non-core (see HERE). Noting the lack of recent accounts, following an extension of its accounting period, there have been no numbers since the period ending July 2014 – figures which were filed very late (14 months post period), and which showed net current assets of MINUS £12,615 and net assets of MINUS £166,078 and £831,528 of losses had been racked up over about seven years (with about £45,000 during the year to July 2014).


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 09:51:15